Physician profile
David C Walker
NPI 1639142508
$3,237.65
in general payments reported to CMS, 2019-2025
25 companies · $665 in 2025
The $665 reported for 2025 was more than what 78% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $201 · 2020: $190 · 2021: $242 · 2022: $590 · 2023: $618 · 2024: $732 · 2025: $665.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,014 · Education: $0.70.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,013.75 |
| Education | $0.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $877.27 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Glaxosmithkline, LLC. | $499.38 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Lilly USA, LLC | $456.00 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $314.60 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $143.40 | 2019-2025 | Evenity, Prolia, Otezla |
| Abbott Laboratories | $120.35 | 2021-2023 | Freestyle Libre 3 |
| Boehringer Ingelheim Pharmaceuticals, INC. | $101.01 | 2019-2024 | Ofev |
| Insmed, INC. | $83.05 | 2025 | Arikayce, Brinsupri |
| Merck Sharp & Dohme LLC | $77.35 | 2019-2024 | Gardasil 9, Vaxneuvance, Pneumovax 23 |
| Abbvie INC. | $76.19 | 2022-2023 | Vraylar |
| Sanofi-Aventis U.S. LLC | $63.06 | 2019-2022 | |
| Exact Sciences Corporation | $47.64 | 2023-2024 | Cologuard Collection Kit |
| Astellas Pharma US INC | $38.20 | 2020-2025 | Veozah |
| Inspire Medical Systems, INC. | $36.66 | 2024 | Inspire |
| Pfizer INC. | $36.42 | 2019-2021 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $35.84 | 2023-2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $34.23 | 2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $31.49 | 2021-2022 | |
| Eisai INC. | $29.41 | 2020-2022 | |
| E.R. Squibb & Sons, L.L.C. | $28.17 | 2022-2024 | Eliquis |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $26.62 | 2025 | Caplyta |
| Ibsa Pharma INC. | $23.70 | 2025 | Tirosint, Flector, Licart |
| Jazz Pharmaceuticals INC. | $21.80 | 2022 | |
| Janssen Pharmaceuticals, INC | $19.34 | 2022 | |
| Organon LLC | $16.47 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Walker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.